• Molecular NameRaloxifene
  • SynonymLY-139481; RAL; raloxifene; Raloxifene Hcl; Raloxifene Hydrochloride; Raloxifeno [Spanish]; Raloxifenum [Latin]
  • Weight473.593
  • Drugbank_IDDB00481
  • ACS_NO84449-90-1
  • Show 3D model
  • LogP (experiment)5.749
  • LogP (predicted, AB/LogP v2.0)5.64
  • pkaN/A
  • LogD (pH=7, predicted)4.19
  • Solubility (experiment)0.00025 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-4.49
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors2
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds7
  • TPSA98.24
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women.
  • Absorption_value60.0
  • Absorption (description)Approximately 60% absorption from the gastrointestinal tract; not significantly affected by food.
  • Caco_2N/A
  • Bioavailability2.0
  • Protein binding95.0
  • Volume of distribution (VD)31 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmUndergoes extensive first-pass metabolism (UGT-catalyzed) and enterohepatic recycling, CYP system not involved
  • Half life27.7 h
  • ExcretionFecal
  • Urinary Excretion<0.2
  • Clerance735 ml/min/kg
  • ToxicityThe most serious adverse reaction related to Raloxifene was venous tromboembolism (deep venous thrombosis, pulmonary embolism, and retinal vein thrombosis).Common adverse reactions considered to be related to EVISTA therapy were hot flashes and leg cramps.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A